Phase II trial of esorubicin (4′deoxydoxorubicin, DxDx) in patients with small cell lung cancer

James R. Rigas, Mark G. Kris, Richard J. Gralla, Robert T. Heelan, Linda D. Marks

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Esorubicin (4′-deoxydoxorubicin or DxDx) is an analog of doxorubicin with preclinical antitumor activity and no significant cardiotoxicity in model systems. Eleven patients with small cell lung cancer who had previously received chemotherapy were given esorubicin (25 mg/m2 intravenously) every 3 weeks. No major objective responses were observed (95% confidence limits: 0-25%). Nine of the 11 patients had grade 2 or greater toxicity, with 55% of the patients experiencing grade 3 or greater toxicity [myelosuppression (4/11), anemia (2/11) or elevated liver enzymes (3/11)]. Nausea, vomiting, alopecia and intravenous site phlebitis were also seen. Three of the 11 patients received 3 or more course of esorubicin without evidence of significant cardiotoxicity. At this dose and shedule, no significant antitumor response were seen in this population of patients. Esorubicin, with this low response rate and significant toxicity, appears to be of limited utility in this disease.

Original languageEnglish (US)
Pages (from-to)187-190
Number of pages4
JournalInvestigational New Drugs
Volume9
Issue number2
DOIs
StatePublished - May 1991
Externally publishedYes

Fingerprint

Small Cell Lung Carcinoma
Phlebitis
Alopecia
Doxorubicin
Nausea
Vomiting
Anemia
esorubicin
Drug Therapy
Liver
Enzymes
Population
Cardiotoxicity

Keywords

  • deoxydoxorubicin
  • esorubicin
  • phase II trial
  • small cell lung cancer

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Phase II trial of esorubicin (4′deoxydoxorubicin, DxDx) in patients with small cell lung cancer. / Rigas, James R.; Kris, Mark G.; Gralla, Richard J.; Heelan, Robert T.; Marks, Linda D.

In: Investigational New Drugs, Vol. 9, No. 2, 05.1991, p. 187-190.

Research output: Contribution to journalArticle

Rigas, James R. ; Kris, Mark G. ; Gralla, Richard J. ; Heelan, Robert T. ; Marks, Linda D. / Phase II trial of esorubicin (4′deoxydoxorubicin, DxDx) in patients with small cell lung cancer. In: Investigational New Drugs. 1991 ; Vol. 9, No. 2. pp. 187-190.
@article{982ebd9dd72945ffbc88a50a327e5685,
title = "Phase II trial of esorubicin (4′deoxydoxorubicin, DxDx) in patients with small cell lung cancer",
abstract = "Esorubicin (4′-deoxydoxorubicin or DxDx) is an analog of doxorubicin with preclinical antitumor activity and no significant cardiotoxicity in model systems. Eleven patients with small cell lung cancer who had previously received chemotherapy were given esorubicin (25 mg/m2 intravenously) every 3 weeks. No major objective responses were observed (95{\%} confidence limits: 0-25{\%}). Nine of the 11 patients had grade 2 or greater toxicity, with 55{\%} of the patients experiencing grade 3 or greater toxicity [myelosuppression (4/11), anemia (2/11) or elevated liver enzymes (3/11)]. Nausea, vomiting, alopecia and intravenous site phlebitis were also seen. Three of the 11 patients received 3 or more course of esorubicin without evidence of significant cardiotoxicity. At this dose and shedule, no significant antitumor response were seen in this population of patients. Esorubicin, with this low response rate and significant toxicity, appears to be of limited utility in this disease.",
keywords = "deoxydoxorubicin, esorubicin, phase II trial, small cell lung cancer",
author = "Rigas, {James R.} and Kris, {Mark G.} and Gralla, {Richard J.} and Heelan, {Robert T.} and Marks, {Linda D.}",
year = "1991",
month = "5",
doi = "10.1007/BF00175087",
language = "English (US)",
volume = "9",
pages = "187--190",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - Phase II trial of esorubicin (4′deoxydoxorubicin, DxDx) in patients with small cell lung cancer

AU - Rigas, James R.

AU - Kris, Mark G.

AU - Gralla, Richard J.

AU - Heelan, Robert T.

AU - Marks, Linda D.

PY - 1991/5

Y1 - 1991/5

N2 - Esorubicin (4′-deoxydoxorubicin or DxDx) is an analog of doxorubicin with preclinical antitumor activity and no significant cardiotoxicity in model systems. Eleven patients with small cell lung cancer who had previously received chemotherapy were given esorubicin (25 mg/m2 intravenously) every 3 weeks. No major objective responses were observed (95% confidence limits: 0-25%). Nine of the 11 patients had grade 2 or greater toxicity, with 55% of the patients experiencing grade 3 or greater toxicity [myelosuppression (4/11), anemia (2/11) or elevated liver enzymes (3/11)]. Nausea, vomiting, alopecia and intravenous site phlebitis were also seen. Three of the 11 patients received 3 or more course of esorubicin without evidence of significant cardiotoxicity. At this dose and shedule, no significant antitumor response were seen in this population of patients. Esorubicin, with this low response rate and significant toxicity, appears to be of limited utility in this disease.

AB - Esorubicin (4′-deoxydoxorubicin or DxDx) is an analog of doxorubicin with preclinical antitumor activity and no significant cardiotoxicity in model systems. Eleven patients with small cell lung cancer who had previously received chemotherapy were given esorubicin (25 mg/m2 intravenously) every 3 weeks. No major objective responses were observed (95% confidence limits: 0-25%). Nine of the 11 patients had grade 2 or greater toxicity, with 55% of the patients experiencing grade 3 or greater toxicity [myelosuppression (4/11), anemia (2/11) or elevated liver enzymes (3/11)]. Nausea, vomiting, alopecia and intravenous site phlebitis were also seen. Three of the 11 patients received 3 or more course of esorubicin without evidence of significant cardiotoxicity. At this dose and shedule, no significant antitumor response were seen in this population of patients. Esorubicin, with this low response rate and significant toxicity, appears to be of limited utility in this disease.

KW - deoxydoxorubicin

KW - esorubicin

KW - phase II trial

KW - small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=0025767657&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025767657&partnerID=8YFLogxK

U2 - 10.1007/BF00175087

DO - 10.1007/BF00175087

M3 - Article

VL - 9

SP - 187

EP - 190

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 2

ER -